SCHEMBL7181892

SCHEMBL7181892

O=C(NC1Cc2ccccc2C1)[C@H]1CC[C@H](Nc2nc3ccccc3[nH]2)CC1

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ NPC1 O15118 5/20 0.55
▸ RAB9A P51151 5/20 0.55
▸ POLB P06746 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ HDAC6 Q9UBN7 1/20 0.46
▸ KCNN3 Q9UGI6 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ PKM P14618 1/20 0.45
▸ ADORA2A P29274 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181901 0.84 HDAC6 (0.58) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7082045 0.82 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7544328 0.82 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7172907 0.82 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7679736 0.81 SMN1; SMN2 (0.70) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7681441 0.81 SMN1; SMN2 (0.70) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7691372 0.81 SMN1; SMN2 (0.70) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL3546237 0.81 KCNN3 (0.57) SMN1; SMN2NPC1RAB9ATDP1HDAC6
SCHEMBL28406604 0.80 HDAC6 (0.57) SMN1; SMN2NPC1RAB9APOLBTDP1
SCHEMBL7085654 0.79 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9APOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244639-A4 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-02-05 — — EP claimed
EP-1244639-A1 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 — — EP claimed
US-6291499-B1 TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE MERCK & CO., INC. 2001-09-18 — — US claimed
WO-2001032634-A1 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 — — WO claimed
EP-1244639-A4 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-02-05 — — EP disclosed
EP-1244639-A1 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 — — EP disclosed
US-6380205-B1 QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN MERCK & CO., INC. 2002-04-30 — — US disclosed
US-6291499-B1 TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE MERCK & CO., INC. 2001-09-18 — — US disclosed
WO-2001032634-A1 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 — — WO disclosed
Send feedback